<DOC>
	<DOC>NCT00604708</DOC>
	<brief_summary>The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged &gt; or = 18 years</brief_summary>
	<brief_title>Immunogenicity Study of the Japanese Encephalitis Vaccine IC51</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At least 18 years of age Written informed consent obtained prior to study entry History of clinical manifestation of any flavivirus infection History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an antiJEV neutralizing antibody titer &gt;= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the perprotocol analysis) Use of any other investigational or nonregistered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine Immunodeficiency including postorgantransplantation or immunosuppressive therapy A family history of congenital or hereditary immunodeficiency History of autoimmune disease Any acute infections within 4 weeks prior to enrollment Infection with HIV, Hepatitis B or Hepatitis C Pregnancy, lactation or unreliable contraception in female subjects</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>